Lukas Biomedical (ROCO:6814) Accounts Payable: NT$4.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6814 Lukas Biomedical Inc ROCO:6814
65 GF Score
Price NT$24.20
GF Value NT$21.72
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lukas Biomedical Accounts Payable?

Lukas Biomedical ROCO:6814 +0.83% 65 Accounts Payable is NT$4.1 Mil as of Dec. 2025. GuruFocus rates ROCO:6814 with a GF Score™ of 65/100 and a GF Value™ of NT$21.72 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Lukas Biomedical's Accounts Payable for the quarter that ended in Dec. 2025 was NT$4.1 Mil.

Lukas Biomedical's quarterly Accounts Payable increased from Dec. 2024 (NT$5.7 Mil) to Jun. 2025 (NT$5.9 Mil) but then declined from Jun. 2025 (NT$5.9 Mil) to Dec. 2025 (NT$4.1 Mil).

Lukas Biomedical's annual Accounts Payable declined from Dec. 2023 (NT$7.0 Mil) to Dec. 2024 (NT$5.7 Mil) and declined from Dec. 2024 (NT$5.7 Mil) to Dec. 2025 (NT$4.1 Mil).

Lukas Biomedical Accounts Payable Related Terms

Lukas Biomedical Accounts Payable Historical Data

* Premium members only.

The historical data trend for Lukas Biomedical's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical Accounts Payable Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 3.02 8.99 6.95 5.71 4.11

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.95 7.40 5.71 5.94 4.11
ROCO:6814
65GF Score
Lukas Biomedical Inc ROCO:6814
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lukas Biomedical Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of NT$4.1 Mil mean?
Lukas Biomedical (ROCO:6814) has a Accounts Payable of NT$4.1 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lukas Biomedical and its competitors.
Is Lukas Biomedical's Accounts Payable too high?
Lukas Biomedical's current Accounts Payable is NT$4.1 Mil. Overall, Lukas Biomedical has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's Accounts Payable compare to VRTX and REGN?
Lukas Biomedical's Accounts Payable of NT$4.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lukas Biomedical and its competitors. Lukas Biomedical's current Accounts Payable is NT$4.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.72, compared to a current price of NT$24.20 — trading 11.4% above its estimated fair value. The current Accounts Payable is NT$4.1 Mil. Lukas Biomedical's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current Accounts Payable is NT$4.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?

Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued. The current stock price of NT$24.20 is trading 11.4% above its estimated GF Value™ of NT$21.72. GuruFocus considers Lukas Biomedical to be Modestly Overvalued.

Key valuation signals for ROCO:6814:

  • Accounts Payable: NT$4.1 Mil
  • GF Value™: NT$21.72 vs. price of NT$24.20 (11.4% above fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lukas Biomedical Business Description

Address No. 14-16, Zhongxiao Road, 1st Floor, Banqiao District, New Taipei City, TWN, 220
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
65GF Score

Get the complete analysis for ROCO:6814

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.20
Price
NT$21.72
GF Value